Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zimislecel - Vertex Pharmceuticals

Next Previous
Drug Profile

Zimislecel - Vertex Pharmceuticals

Alternative Names: Allogeneic human stem cell-derived islet cell therapy - Vertex Pharmaceuticals; Stem cell-derived beta cells - Vertex Pharmaceuticals; Stem cell-derived fully differentiated pancreatic islet cell therapy - Vertex Pharmaceuticals; STx-02; VX-880

Latest Information Update: 09 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Semma Therapeutics
  • Developer Vertex Pharmaceuticals
  • Class Cell therapies; Stem cell therapies
  • Mechanism of Action Pancreatic beta cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Type 1 diabetes mellitus

Most Recent Events

  • 28 Mar 2025 Vertex Pharmaceuticals announces intention to file regulatory application for Type 1 diabetes mellitus globally in 2026
  • 28 Mar 2025 Zimislecel receives Innovation Passport designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Type 1 diabetes mellitus before March 2025
  • 25 Mar 2025 Vertex Pharmaceuticals initiates a phase II trial for Type 1 diabetes mellitus in Canada (Intrahepatic, Infusion) (NCT06832410)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top